Inhibikase expects to begin a Phase 2a study of IkT-148009, its investigational therapy for Parkinson’s disease, in the…
Articles by Margarida Maia, PhD
Treatment with the low-dose painkiller ketamine eased levodopa-induced dyskinesia (uncontrollable body movements) in patients with Parkinson’s disease, according to results…
SQZ Biotechnologies has received a $2 million grant to work out a way to turn a patient’s own immune…
A form of the alpha-synuclein protein that can build up in the skin could help distinguish Parkinson’s disease from…
Excessive sweating, known as hyperhidrosis, is fairly common among people with Parkinson’s and can worsen as the disease progresses,…
Machine learning — a form of artificial intelligence that allows a computer to adapt, analyze, and infer from patterns in…
A protein modification that disrupts how cells dispose of “worn-out” proteins may promote the spread of the alpha-synuclein toxic clumps…
SMARTfit gym equipment, which combines movement with cognitive tasks in a playful way, may lead to better motor and cognitive…
Mutations in the enzyme glucocerebrosidase (GCase) prevent it from entering the lysosome — a cell’s recycling center — where it clears…
IMAC Holdings has completed dosing the second group of patients in its Phase 1 clinical trial testing umbilical cord-derived…